Abstract 232P
Background
SY-1365 is a first-in-class, potent, selective covalent CDK7 inhibitor currently under phase I evaluation in expansion cohorts including ovarian cancer (OC) patients (pts) to assess safety, biologic and anti-tumor activity of SY-1365 alone and in combination with carboplatin (CP), and correlation of activity with RB pathway changes (RbC).
Methods
Expansion cohort pts received single agent (SA) SY-1365 BIW at doses ranging from 53-80 mg/m2 administered IV over 1 or 2 hrs for 3 of 4 wks/cycle. CP was given at AUC4 or 5 on day 1 of a 3 wk cycle with SY-1365 at 53 mg/m2 QW days 1 and 8. Clinical activity and safety were assessed by RECIST 1.1 and CTCAEv5, respectively. Apoptotic and cell proliferation markers were evaluated in tumor tissue from pts with paired biopsies. RbC in tumor and plasma samples were evaluated for correlation with SY-1365 activity.
Results
As of 6/14/19, 80 total pts were enrolled, 33 in dose escalation, and 47 in expansion cohorts including 15 receiving SA and 3 receiving SY-1365+CP that were evaluated for response. Overall median duration (N=80) on SY-1365 treatment was 30.5 days (1-232). Adverse events (AEs) were generally low grade and reversible, occurring mostly on the day of dosing. Frequent (≥15%) AEs of any causality included headache, nausea, vomiting, fatigue, diarrhea, decreased appetite, abdominal pain, thrombocytopenia, anemia, infusion-related reaction, and dehydration. There were no treatment-related deaths. Of the expansion pts evaluated for response, 33% (5/15) receiving SA and 100% (3/3) receiving SY-1365+CP had SD as the best response, with the longest pt on SA for 114 days and on CP combination for 232 days. Available tumor biopsies demonstrate evidence of apoptosis in post-dose tumor tissue in 3 of 4 pts, with early evidence of RbC associated with SD in OC pts.
Conclusions
Emerging tolerability findings suggest predominantly low grade, reversible AEs, primarily on days of dosing. Early clinical activity demonstrates SD in both SA and CP combination cohorts with evidence supporting increased apoptosis in tumor tissue and associations of clinical activity with RbC. PK/PD guided dose optimization is in progress. Updated data will be presented.
Clinical trial identification
NCT03134638 - May 1, 2017
Editorial acknowledgement
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract